Algernon Pharmaceuticals receives ethics approval as the company begins clinical trials for Ifenprodil

Algernon Pharmaceuticals receives ethics approval as the company begins clinical trials for Ifenprodil

 

 

Algernon Pharmaceuticals Inc. (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling to announce the company has received ethics approval from a central institutional review board for U.S. study sites for its multinational Phase 2b/3 human study of Ifenprodil for COVID-19.

Moreau explains what that means going forward and he also updates the market on the company’s general progress regarding the trials as well as other business activities.

 

original article: https://ca.proactiveinvestors.com/companies/news/922805/algernon-pharmaceuticals-receives-ethics-approval-as-they-begin-clinical-trials-for-ifenprodil-922805.html

Share via
Copy link
Powered by Social Snap